Publications by authors named "D Kolte"
Use of Claims to Assess Outcomes and Treatment Effects in the Evolut Low Risk Trial.
Circ Cardiovasc Interv
January 2025
Background: Food and Drug Administration-mandated postmarket studies for transcatheter aortic valve replacement in low-risk populations plan to use passively collected registry data linked to claims for long-term follow-up out to 10 years. Therefore, it is critically important to understand the validity of these claims-based end points. We sought to evaluate the ability of administrative claims with () codes to identify trial-adjudicated end points and reproduce treatment comparisons of aortic valve replacement in the Evolut Low Risk Trial.
View Article and Find Full Text PDFQuantum leap in the diagnosis of oral potentially malignant disorders - A review of literature.
Natl J Maxillofac Surg
November 2024
Early diagnosis of oral potentially malignant disorders (OPMDs) can bring about considerable improvement in reducing the statistics related to morbidity and mortality associated with oral cancer. The objective of this review was to summarize advanced diagnostic aids used for OPMDs. Pubmed, Embase, and Cochrane Central Register of Controlled Trials electronic databases from 1969 to 2022 focus on advanced diagnostic techniques for potentially malignant disorders.
View Article and Find Full Text PDFRelationship Between Hospital Mortality and Readmission Rates After Transcatheter Aortic Valve Replacement.
Eur Heart J Qual Care Clin Outcomes
November 2024
Background: There is substantial hospital-level variation in 30-day risk-standardized mortality rate (RSMR) and risk-standardized readmission rate (RSRR) after transcatheter aortic valve replacement (TAVR). However, the relationship between hospital RSMRs and RSRRs has not been well characterized.
Methods: We analyzed data on 141,905 Medicare fee-for-service beneficiaries who underwent TAVR across 512 hospitals between October 1, 2015 and December 31, 2020.
Background: Several transcatheter tricuspid valve (TV) repair devices for tricuspid regurgitation (TR) have emerged. However, few studies have compared transcatheter TV repair with medical therapy (MT) alone or isolated TV surgery.
Methods: PubMed and EMBASE were searched in February 2024.
Article Synopsis
- The study compares two treatment methods for patients with tricuspid regurgitation: tricuspid transcatheter edge-to-edge repair (T-TEER) and surgical tricuspid valve repair, focusing on outcomes like two-year all-cause mortality and other complications.
- Analysis was conducted on 1,143 Medicare beneficiaries aged 65 to 99, revealing no significant difference in two-year mortality rates between the two treatments, but noted a rise in T-TEER procedures over the years.
- T-TEER showed lower in-hospital mortality and fewer cases requiring pacemaker implantation, but more tricuspid valve reinterventions were needed compared to surgical repair, indicating a need for further research on treatment selection and timing